Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue (2018 - 2026)

Kiniksa Pharmaceuticals International has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $31.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $31.8 million; the trailing twelve-month figure through Mar 2026 stood at $31.8 million (changed 0.0% YoY), and the FY2025 full-year result was $31.8 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $31.8 million, roughly flat from $31.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $31.8 million in Q4 2024, with the low at $261000.0 in Q4 2023.
• Historically, Non-Current Deffered Revenue has averaged $18.4 million across 5 years, with a median of $12.0 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue slumped 97.82% — and 2024, when it soared 12088.12%.
• Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue stood at $12.0 million in 2022, then tumbled by 97.82% to $261000.0 in 2023, then soared by 12088.12% to $31.8 million in 2024, then changed by 0.0% to $31.8 million in 2025, then changed by 0.0% to $31.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $31.8 million (Q1 2026), $31.8 million (Q4 2025), and $31.8 million (Q3 2025), per Business Quant data.